Actions

Newsfeed Popular Local Discover Follows Blocks Bookmarks Filters Settings PowerUps Help Updates

investingnews.com / Share Newsitem

View, share or embed this newsitem using the details below.

Results From RMWC Funded Phase II Prostate Cancer Trial using INV043 - Strong Safety Profile and 40% Positive Response Rate

Invion Limited (ASX: IVX) ("Invion" or the "Company") wishes to announce that RMW Cho Group Limited (RMWC), the licensor of the Photosoft technology, has successfully completed a Phase II prostate cancer trial1 (ACTRN12621000633886) using a...

https://newsreadery.com/go/3be9bfc07714edbaf8d424eb7aa00521

Save

Back

Read Full Article